World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: JPRN
Last refreshed on: 1 April 2024
Main ID:  JPRN-jRCT2011210019
Date of registration: 30/06/2021
Prospective Registration: Yes
Primary sponsor: Yokoyama Yoshinari
Public title: Phase 2 double blind study of cenerimod
Scientific title: A randomized, double-blind, parallel-group, multicenter, phase 2 study to investigate the safety and PD of cenerimod in Japanese subjects with moderate to severe systemic lupus erythematosus (SLE)
Date of first enrolment: 06/11/2021
Target sample size: 16
Recruitment status: Complete
URL:  https://jrct.niph.go.jp/latest-detail/jRCT2011210019
Study type:  Interventional
Study design:  randomized controlled trial, double blind, dose comparison control, parallel assignment, treatment purpose  
Phase:  2
Countries of recruitment
Contacts
Name: Yoshinari    Yokoyama
Address:  9-7-2 Akasaka Mitatoku, Tokyo 107-0052 Tokyo Japan
Telephone: +81-03-5962-5616
Email: chiken.info-jp@idorsia.com
Affiliation:  Idorsia Pharmaceuticals Japan Ltd
Name: Yoshinari    Yokoyama
Address:  9-7-2 Akasaka Mitatoku, Tokyo 107-0052 Tokyo Japan
Telephone: +81-3-5962-5616
Email: chiken.info-jp@idorsia.com
Affiliation:  Idorsia Pharmaceuticals Japan Ltd
Key inclusion & exclusion criteria
Inclusion criteria: (1) Signed ICF prior to any study-mandated procedure.
(2) Diagnosis of SLE made at least 6 months prior to Screening, by fulfilling at least 4 of the 11 criteria for SLE as defined by the American College of Rheumatology (ACR) criteria.
(3) Male and female subjects, age 18 to 75 years old (both inclusive).
(4) A mSLEDAI-2K score >= 6 of at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
Note: The mSLEDAI-2K score does not consider the factor leukopenia in SLEDAI-2K.

Exclusion criteria: (1) Female subjects who are lactating or planning to become pregnant during the study.
(2) Active lupus nephritis (defined by proteinuria > 1.5 g/24 h, or equivalent using spot urine protein-to-creatinine ratio > 150 mg/mmol) or a renal biopsy demonstrating immune complex-mediated glomerulonephritis compatible with lupus nephritis within 90 days prior to Screening.
(3) Severe active central nervous system (CNS) lupus requiring therapeutic intervention (including aseptic meningitis, seizures, psychosis, cerebritis, cerebrovascular accident [CVA], organic brain syndrome, CNS vasculitis)
(4) Severe forms of vasculitis requiring systemic immunosuppressive treatment (including retinal vasculitis, coronary vasculitis, pulmonary vasculitis, mesenteric vasculitis) within 90 days prior to Screening.
(5) A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with rheumatoid arthritis, erosive arthritis, scleroderma or autoimmune hepatitis.


Age minimum: >= 18age old
Age maximum: <= 75age old
Gender: Both
Health Condition(s) or Problem(s) studied
Systemic lupus erythematosus
Intervention(s)
Administration of two doses of cenerimod (2 and 4 mg) given orally once daily for 3 months in adult subjects with moderate to severe SLE concurrently receiving SLE background treatment
Primary Outcome(s)
Occurrence of treatment-emergent AEs/SAEs, and AEs of following special interest:
HR and rhythm-related AEs
Hypotension-related AEs
Hypertension-related AEs
etc.
Secondary Outcome(s)
Change from baseline to each post-baseline assessment up to EOS in total lymphocyte count
Secondary ID(s)
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Status: Approval
Approval date:
Contact:
hassi@med.hokudai.ac.jp
Hokkaido University Hospital Institutional Review Board
+81-11-706-7061
hassi@med.hokudai.ac.jp
Results
Results available: Yes
Date Posted:
Date Completed: 16/02/2023
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey